27 58

Cited 0 times in

The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma

DC FieldValueLanguage
dc.contributor.author김대준-
dc.contributor.author김혜련-
dc.contributor.author박성용-
dc.contributor.author이창걸-
dc.contributor.author조병철-
dc.contributor.author조재호-
dc.contributor.author홍민희-
dc.date.accessioned2021-01-19T07:50:04Z-
dc.date.available2021-01-19T07:50:04Z-
dc.date.issued2020-11-
dc.identifier.issn2072-1439-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181343-
dc.description.abstractBackground: Immune checkpoint inhibitors have been tried for several thoracic malignancies; however, their application as a neoadjuvant therapy in esophageal squamous cell carcinoma (ESCC) has not been studied. We evaluated the feasibility and safety of esophagectomy and total lymphadenectomy after neoadjuvant chemoradiation therapy with pembrolizumab. Methods: Between 2017 and 2018, 38 patients who received the neoadjuvant therapy followed by radical esophagectomy and total lymphadenectomy for ESCC were analyzed. Twenty-two patients received conventional neoadjuvant chemoradiation therapy (Group 1), and sixteen patients received neoadjuvant chemoradiation therapy with pembrolizumab in clinical trial (Group 2). Two groups were compared retrospectively. Results: The basic characteristics of age, clinical stage, location and methods of operation were not different between the two groups. The pathologic stages were higher in Group 2, but the difference was not statistically significant. The operative outcomes, i.e., operation time, blood loss, and numbers of dissected lymph nodes in the thorax, neck, and abdomen were comparable. Complications, including pulmonary complications and anastomotic leakage, were also comparable. The rate of recurrent laryngeal nerve palsy was also comparable between the two groups (31.8% vs. 18.8%, P=0.469). Operative mortalities developed in 2 patients [0 vs. 2 (12.5%), P=0.171] due to acute respiratory distress syndrome (ARDS). Conclusions: Radical esophagectomy for esophageal squamous cell carcinoma after neoadjuvant chemoradiation therapy with pembrolizumab may not increase the operative risk or reduce the quality of radical dissection including lymphadenectomy. The risk of ARDS after neoadjuvant neoadjuvant chemoradiation therapy with pembrolizumab has to be studied in the further analysis.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherPioneer Bioscience Pub. Co.-
dc.relation.isPartOfJOURNAL OF THORACIC DISEASE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleThe feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Thoracic and Cardiovascular Surgery (흉부외과학교실)-
dc.contributor.googleauthorSeong Yong Park-
dc.contributor.googleauthorMin Hee Hong-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorChang Geol Lee-
dc.contributor.googleauthorJae Ho Cho-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorDae Joon Kim-
dc.identifier.doi10.21037/jtd-20-1088-
dc.contributor.localIdA00368-
dc.contributor.localIdA01166-
dc.contributor.localIdA01166-
dc.contributor.localIdA01508-
dc.contributor.localIdA01508-
dc.contributor.localIdA03240-
dc.contributor.localIdA03240-
dc.contributor.localIdA03822-
dc.contributor.localIdA03822-
dc.contributor.localIdA03901-
dc.contributor.localIdA03901-
dc.contributor.localIdA04393-
dc.contributor.localIdA04393-
dc.relation.journalcodeJ01907-
dc.identifier.eissn2077-6624-
dc.identifier.pmid33282345-
dc.subject.keywordEsophagectomy-
dc.subject.keywordimmune checkpoint inhibitors-
dc.subject.keywordneoadjuvant therapy-
dc.subject.keywordoperative outcomes-
dc.contributor.alternativeNameKim, Dae Joon-
dc.contributor.affiliatedAuthor김대준-
dc.contributor.affiliatedAuthor김혜련-
dc.contributor.affiliatedAuthor김혜련-
dc.contributor.affiliatedAuthor박성용-
dc.contributor.affiliatedAuthor박성용-
dc.contributor.affiliatedAuthor이창걸-
dc.contributor.affiliatedAuthor이창걸-
dc.contributor.affiliatedAuthor조병철-
dc.contributor.affiliatedAuthor조병철-
dc.contributor.affiliatedAuthor조재호-
dc.contributor.affiliatedAuthor조재호-
dc.contributor.affiliatedAuthor홍민희-
dc.contributor.affiliatedAuthor홍민희-
dc.citation.volume12-
dc.citation.number11-
dc.citation.startPage6426-
dc.citation.endPage6434-
dc.identifier.bibliographicCitationJOURNAL OF THORACIC DISEASE, Vol.12(11) : 6426-6434, 2020-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.